Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHR160 spray for patients with COVID-19
IRCT20200731048257N1Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing PHR160 spray plus background regimen with Placebo spray plus background regimen (2 arms). Primary endpoint: Shortness of breath. Started Aug 2020; status: completed.
02
Drugs
PHR160
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200731048257N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200731048257N1.